Neurotronic to Present First Clinical Outcomes for Multi-Organ Denervation in Type 2 Diabetes and Hypertension

Neurotronic, Inc., a U.S.-based medical technology company developing multi-organ denervation therapies for cardiovascular and metabolic diseases, announced upcoming presentations of the first clinical outcomes from its Neuviant™ Multi-organ Denervation (MDN) system.

The results will be shared at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 meeting in San Francisco and represent the first reported human data on a therapy designed to modulate multiple overactive sympathetic pathways — commonly linked to type 2 diabetes mellitus (T2DM) and hypertension (HTN).

Findings from the NECTAR III and NECTAR IV clinical studies evaluated the safety, performance, and efficacy of hepatic and bilateral renal denervation using Neurotronic’s investigational Neuviant MDN System. The single-arm studies enrolled patients with both T2DM and HTN, including those whose conditions remained uncontrolled despite medication.

The data will be presented by Professor Dr. Horst Sievert, Director of CardioVascular Center Frankfurt, and Dr. Ajay J. Kirtane, Director of Columbia Interventional Cardiovascular Care at Columbia University Medical Center, during two sessions on October 26 and 27.

The Neuviant MDN procedure delivers dehydrated ethanol via catheter to the tissue surrounding the hepatic and renal arteries. The approach is designed to disrupt overactive sympathetic nerve signaling, with the aim of reducing both elevated blood sugar and high blood pressure.

The presentations are scheduled as follows:

• Title: Multi-organ Arterial Denervation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR IV Trial)
  Presenter: Prof. Dr. Horst Sievert
  Session: Best Endovascular Intervention Abstracts
  Date/Time: Sunday, October 26, 2025, 12:10–12:20 p.m.
  Location: Station 8, Halls B–C, Moscone South
• Title: Multi-organ Ethanol Denervation to Treat Type 2 Diabetes Mellitus and Hypertension: 6-Month Results of an Early Feasibility Study
  Presenter: Dr. Ajay J. Kirtane
  Session: Innovation Session 7: Percutaneous Denervation for the Treatment of Chronic Diseases
  Date/Time: Monday, October 27, 2025, 7:49–8:00 a.m.
  Location: Innovation Theater, Hall E, Moscone North

The Neuviant MDN System, which combines the Neuviant MDN Catheter and the ethanol-based agent Simpathol™, remains investigational and is currently being studied as a treatment for T2DM and HTN.

Founded in 2015, Neurotronic, Inc. develops multi-organ denervation therapies targeting sympathetic overactivity implicated in chronic cardiovascular and metabolic diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!